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ABSTRACT  
Background and aims 
Little information is available on real-life occurrence of oral thrush in COPD patients 
treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC 
ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and 
delivery device. 
Methods 
We conducted a historical, observational, matched cohort study (one baseline year before 
and one outcome year after initiation of therapy) using data from the UK Optimum Patient 
Care Research Database. We assessed oral thrush incidence in patients initiating long-
acting bronchodilators or FDC ICS/LABA therapy. We then compared different 
combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and 
fluticasone propionate/salmeterol xinafoate [FP/SAL]) and devices (DPI and pMDI). 
Results 
Patients prescribed FDC ICS/LABA had significantly greater odds of experiencing oral 
thrush than those prescribed long-acting bronchodilators alone (adjusted OR 2.18 [95% CI 
1.84–2.59]). Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush 
compared with FP/SAL DPI (OR 0.77 [0.63–0.94]) when allowing for differences in 
prescribed doses between the drugs. A significantly smaller proportion of patients 
developed oral thrush in the FP/SAL pMDI arm than in the FP/SAL DPI arm (OR 0.67 
[0.55–0.82]). Additionally, in the FP/SAL cohort (both DPI and pMDI), increased risk of 
oral thrush was significantly associated with high ICS daily dose (OR 1.97 [1.22–3.17] vs 
low daily dose).  
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Conclusions 
ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for 
FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be 
more protective against oral thrush.  
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INTRODUCTION 
Oral thrush, also known as oral candidiasis, is a well-documented local side-effect 
associated with regular inhaled corticosteroid (ICS) use in patients with asthma1-4. It is 
thought to be caused by a reduced local immune response5 or an increase in salivary 
glucose (which stimulates growth of Candida albicans6) after deposition of ICS in the 
oropharyngeal cavity. Many factors have been reported to influence the incidence of oral 
thrush in asthma, including type and dose of ICS used, mode of drug delivery, and patient 
compliance with medication instructions7-11. Although generally associated with 
temporary symptoms, ICS local side-effects, including oral thrush, can be clinically 
significant, and may affect patient quality of life and therapy adherence3,12,13.  
ICS are also prescribed for the treatment of chronic obstructive pulmonary disease 
(COPD) in patients with severe airflow limitation and/or at high risk of exacerbations, and  
are generally recommended in combination with long-acting β2-agonists (LABAs)14,15. 
However, recent studies have found that ICS are being prescribed in COPD even more 
widely and frequently than would be expected from current management guidelines, 
particularly among less severe patients16,17. Despite the widespread use of ICS in this 
disease, there is little information on real-life occurrence and distribution of oral thrush in 
patients with COPD who are prescribed ICS18-21. The objective of this study was to 
investigate the incidence of oral thrush in COPD patients receiving ICS as part of their 
ICS/LABA combination therapy. In particular, we sought to assess whether oral thrush 
incidence is modulated by the type of ICS, the ICS dose, and the delivery device (dry 
powder inhaler [DPI] vs pressurised metered-dose inhaler [pMDI]). 
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METHODS 
Study design and data source 
This was a historical, observational, matched cohort study utilising healthcare records 
from the Optimum Patient Care Research Database (OPCRD)22. The OPCRD is a bespoke 
database with focus on patient-reported outcomes that, at the time of this study, contained 
anonymous data for over 2.4 million patients from over 550 UK primary care practices 
across England, Scotland, Wales, and Northern Ireland. It contains two types of data: (1) 
routinely recorded clinical data and (2) questionnaire responses from over 40,000 patients 
with respiratory conditions. We examined data during a one-year baseline period (prior to 
the index date, defined below) for patient characterisation, and a one-year outcome period 
after initiation of a new or additional COPD therapy. The index date was defined as the 
date of first prescription for either a fixed dose combination (FDC) ICS/LABA (therapies 
assessed described below) or long-acting bronchodilator therapy (LABA, long-acting 
muscarinic antagonist [LAMA], or their combination; addition of an alternative long-
acting bronchodilator was also considered as first prescription). This study design was 
necessary to determine the incidence of oral thrush, compared with a reference group 
without ICS exposure, and allow for seasonal changes in respiratory disease symptoms 
and related conditions. The study was conducted to standards suggested for observational 
studies, including an independent advisory group, use of an a priori analysis plan, study 
registration with commitment to publish, and a well-maintained and monitored study 
database23. 
Ethical approval  
The study was conducted and is reported in compliance with the criteria of the European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP; 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
7 
registration number: ENCEPP/SDPP/12762). OPCRD received a favourable opinion from 
the Health Research Authority for clinical research use (REC reference: 15/EM/0150). Its 
governance is provided by The Anonymous Data Ethics Protocols and Transparency 
(ADEPT) committee (http://optimumpatientcare.org/our-database/), an independent body 
of experts and regulators commissioned by the Respiratory Effectiveness Group (REG, 
http://www.effectivenessevaluation.org/) to govern the standard of research conducted on 
internationally recognised databases (ADEPT approval reference for this study: 
ADEPT1416). 
Inclusion and exclusion criteria 
Patients eligible for inclusion in the study received a quality outcomes framework (QOF) 
code for COPD diagnosis24, were aged ≥40 years at the index date, had at least 2 years of 
continuous practice data (1 year of baseline and 1 year of outcome data), and received ≥2 
prescriptions of FDC ICS/LABA or long-acting bronchodilator during the outcome period 
(including prescriptions at the index date). Patients were excluded if in the baseline period 
they received ≥1 prescription for ICS, ≥1 prescription for both LABA and LAMA, 
maintenance oral corticosteroid prescription, or if they had a diagnostic code for any 
chronic respiratory disease other than COPD, asthma, or bronchiectasis. 
Cohorts and treatment arms  
We initially studied two cohorts of patients with COPD. The first cohort included patients 
that were prescribed FDC ICS/LABA combination therapy at the index date. Combination 
therapy included the following: budesonide/formoterol fumarate dihydrate (BUD/FOR) 
administered via a DPI device (Symbicort® Turbohaler®); fluticasone 
propionate/salmeterol xinafoate (FP/SAL; Seretide®) administered via DPI (Accuhaler®) 
or pMDI (Evohaler®) device; and beclometasone dipropionate/formoterol fumarate 
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dihydrate (BDP/FOR; Fostair®) administered via a DPI (NEXThaler®) or pMDI device. 
Patients prescribed BDP/FOR DPI were not included in the subsequent analyses owing to 
their low number. The second cohort included patients who were prescribed non-ICS 
therapy (any long-acting bronchodilator) at the index date, namely LABA, LAMA or their 
combination. The two cohorts were matched 1:1 (see below and Table S1). Before 
matching, in the non-ICS therapy cohort, patients could have been included more than 
once with different first prescriptions for LABA, LAMA or their combination.   
We then conducted subset analyses dividing patients of the unmatched FDC ICS/LABA 
cohort according to different combination therapies (BUD/FOR DPI and FP/SAL DPI) 
and devices (FP/SAL pMDI and FP/SAL DPI) and matched them 1:1 (see below and 
Figure S1A, B). Finally, in the FP/SAL pMDI treatment arm, we conducted a subgroup 
analysis of patients who were prescribed a spacer in the period comprising the baseline 
year, the index date, and two weeks after the index date (ensuring that spacer device use 
preceded the occurrence of oral thrush), and compared them with patients who were not 
prescribed a spacer in the same period. 
Exact matching  
We used matching with statistical adjustment for residual confounders (exact matching, as 
described in previous studies25,26) in order to ensure that we analysed comparable groups 
of patients. We compiled a list of potential matching criteria informed by expert clinical 
advice and previous research experience, including variables predictive of outcomes and 
the key baseline clinical characteristics differing between unmatched cohorts (identified 
using t-test, and Chi-Squared and Mann-Whitney U tests, as appropriate). The matching 
criteria (described in Table S1 and Figure S1A, B) were then applied sequentially to 
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produce two matched cohorts containing all possible pairings; bespoke software was used 
to randomly select final unique matched pairs.  
ICS daily doses  
To better capture the relationship between ICS dose and oral thrush, we used the intended 
daily dose of ICS, defined as the dose prescribed at the index date. Doses are expressed in 
FP equivalent units (FP: BUD, 1:2 dose ratio; see Table 10 in British Thoracic Society 
[BTS]/Scottish Intercollegiate Guidelines Network [SIGN] British Guideline on the 
Management of Asthma, 201427) and were categorised in low (<500 µg/day), moderate 
(500–999 µg/day), and high (≥1000 µg/day) dose categories based on previous studies28. 
BUD/FOR DPI and FP/SAL DPI are licensed for use in COPD in the UK at recommended 
daily doses of 400 (FP equivalents) and 1000 µg/day, respectively29. FP/SAL pMDI is not 
licensed for use in COPD in the UK, however, as this study indicates, it is widely 
prescribed off-licence for the treatment of COPD.  
Outcomes 
The primary outcome was the incidence of oral thrush, defined as the proportion of 
patients with a diagnosis of oral thrush and/or prescribed antifungal medication for the 
treatment of oral thrush within the outcome period (occurring at distinct dates). Because 
oral thrush is generally successfully treated with antifungal medications 
(http://www.nhs.uk/conditions/Oral-thrush---adults/Pages/Introduction.aspx), different 
episodes can be regarded as independent cases/diagnosis.  
Statistical analysis 
All analyses were carried out using SAS version 9.330, SPSS Statistics version 2231, and R 
version 3.2.332. The study was powered on the primary outcome, incidence of oral thrush. 
The sample size required for a 90% power to reject the null hypothesis (no difference in 
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oral thrush incidence between the study cohorts) estimated a minimum of 360 patients in 
each of the cohorts. This calculation assumed an expected difference in proportions of 
0.05 (π1 = 0.020 and π2 = 0.070; two-group Chi-squared test with 0.05 two-sided 
significance level) based on results from a similar study by Calverley et al. (2007)19. 
For matched data, we used conditional logistic regression to compare oral thrush incidence 
between cohorts and treatment arms. For unmatched data, we used logistic regression. 
Outcomes were adjusted for any residual non-collinear baseline confounders and for those 
demographic and baseline variables predictive of the outcome through full multivariable 
analysis. Results are reported both as number (and percentage) of patients who had a 
diagnosis of oral thrush and/or medication prescribed for oral thrush in the outcome period 
and as odds ratios (OR) with 95% confidence intervals (CI), unadjusted and adjusted for 
confounders. When CI does not contain 1.00, results are statistically significant at the 5% 
level. We used the Chi-Squared test for unmatched comparisons (results are statistically 
significant when p <0.05). 
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RESULTS 
In the unmatched cohorts, we analysed observations from 13,647 patients who were 
prescribed FDC ICS/LABA and 10,043 observations from 9,161 patients who were 
prescribed non-ICS therapy (Figure 1A, B). Matching procedure (Table S1) resulted in a 
final population of 8,255 uniquely matched patients per cohort. We characterised 
unmatched and matched patients according to baseline demographic and clinical features. 
Overall characteristics of the unmatched populations were retained in the matched cohorts 
(Table 1). In the matched cohorts, the mean age was 69 years (SD 10), 57% of patients 
were male, the majority were ex-smokers (50%) or current-smokers (40%), and the mean 
BMI was 27 (SD 6), indicating that the majority of patients were overweight or obese. 
Diabetes (18%), eczema (14-15%), and asthma (7-10%) were the most frequent 
comorbidities. Finally, Table 1 shows that oral thrush prevalence was low in the baseline 
period both in the matched (1%) and in the unmatched cohorts (3%). 
 
Incidence of oral thrush in patients prescribed ICS  
In the outcome period, the incidence of oral thrush was higher in patients prescribed FDC 
ICS/LABA compared with those prescribed non-ICS therapy (Table 2; 456 [5.5%] vs 227 
[2.7%] patients; adjusted OR 2.18 [95% CI 1.84–2.59]). Among the total patients with oral 
thrush, 493 (72.2%) and 118 (17.3%) experienced one episode and two episodes, 
respectively, of oral thrush in the outcome period.  
 
Incidence of oral thrush by ICS drug and inhaler device 
To carry out subset analyses we used matching (Figure S1A, B), which resulted in 3,465 
uniquely matched patients per treatment in the cohort comprising BUD/FOR DPI and 
FP/SAL DPI, and in 3,800 uniquely matched patients per treatment in the cohort 
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comprising FP/SAL pMDI and FP/SAL DPI. Baseline characteristics of these matched 
cohorts are summarised in Table 3.  
Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush compared 
with patients prescribed FP/SAL DPI (Figure 2, top; 196 [5.7%] patients with oral thrush 
vs 244 [7.0%]; OR 0.77 [95% CI 0.63–0.94] after adjusting for baseline confounders). 
However, the majority of patients who were on BUD/FOR DPI therapy were prescribed 
the medication at low ICS dose, whereas most patients on FP/SAL DPI therapy were 
prescribed the medication at higher ICS doses (Table S2). After adjusting for intended ICS 
daily dose, we found no significant difference in the incidence of oral thrush between the 
treatment arms (Figure 2, top; fully adjusted OR 1.04 [95% CI 0.54–2.00]). The ICS dose 
was an expected a priori confounder in this cohort, given that the daily dose recommended 
for use in COPD is different between BUD/FOR and FP/SAL29.  
A significantly smaller proportion of patients developed oral thrush in the FP/SAL pMDI 
arm than in the FP/SAL DPI arm (Figure 2, bottom; adjusted OR 0.67 [95% CI 0.55–
0.82]; 208 [5.5%] patients with oral thrush vs 279 [7.3%]).  
A subgroup analysis revealed that oral thrush incidence was lower among patients 
prescribed FP/SAL pMDI with a spacer device compared with those prescribed FP/SAL 
pMDI without a spacer (Table S3; 35 [4.2%] vs 173 [5.8%]); however, this difference did 
not reach statistical significance (Table S3; adjusted OR 0.74 [95% CI, 0.51–1.07]). 
 
Incidence of oral thrush by ICS dose 
In the cohort comprising FP/SAL pMDI and FP/SAL DPI a significantly higher number of 
patients prescribed high daily dose of ICS (≥1000 µg/day FP equivalent units) developed 
oral thrush compared with those prescribed low daily dose of ICS (<500 µg/day) (Table 4; 
number [%] of patients with oral thrush: low dose, 35 [4.7%]; high dose, 329 [7.2%]; 
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adjusted OR 1.97 [95% CI, 1.22–3.17]). An exploratory analysis within treatment arm 
indicated that the main driver of this difference was FP/SAL pMDI (Table S2; number [%] 
of patients with oral thrush: low dose, 14 [3.6%]; high dose, 132 [6.5%]; unadjusted OR 
1.85 [95% CI, 1.05–3.25] for high vs low comparison; no significant differences were 
detected in the FP/SALDPI arm [Table S2]).  
A similar pattern of increasing odds for oral thrush with increasing ICS dose was observed 
in the cohort comprising BUD/FOR DPI and FP/SAL DPI, however this difference did not 
reach statistical significance (Table 4; number [%] of patients with oral thrush: low dose, 
210 [5.6%]; high dose, 169 [7.4%]; adjusted OR 1.42 [95% CI, 0.70–2.88]). Our 
exploratory analysis within treatment arms confirmed no significant effect of dose for 
either treatment, which for BUD/FOR DPI was due to heavy prescribing at a low daily 
dose (3,411 patients [98.4%], Table S2).  
DISCUSSION  
There is limited research on the real-life incidence of oral thrush in patients with COPD 
who are prescribed ICS. Here, we showed that ICS therapy increases the risk of 
developing oral thrush in real-life patients with COPD and this effect is modulated by the 
delivery device and, for some ICS therapies, by dose.  
We observed a significant reduction in the risk of oral thrush among patients prescribed 
BUD/FOR DPI compared with those prescribed FP/SAL DPI, which was likely 
attributable to the ICS dose prescribing patterns: in UK, the daily dose of FP/SAL DPI that 
is recommended for use in COPD is more than double the FP-equivalent dose of 
BUD/FOR DPI29. After adjusting for this a priori confounder, we observed no significant 
difference in the incidence of oral thrush between the two therapies, suggesting that if the 
drugs were prescribed at the same dose the risk of developing oral thrush would be 
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similar. However, BUD/FOR DPI may represent a better therapeutic option to reduce the 
risk of oral thrush given that it is generally prescribed at lower doses (and thus associated 
with less amount of ICS being deposited in the oropharynx). We considered whether the 
difference in the prescribing patterns could be confounded by the selection of ICS therapy 
by general practitioners, with milder patients being prescribed BUD/FOR DPI and more 
severe patients being prescribed FP/SAL DPI. However, patients were matched on COPD 
exacerbations in the baseline period and other variables related to disease severity (COPD 
therapy, FEV1 % predicted, acute oral corticosteroid courses, and lower respiratory 
consultations in the baseline period) were balanced between the treatment arms. Therefore, 
it is unlikely that disease severity was systematically different between the groups.  
Several studies reported that the incidence of oral thrush is positively associated with the 
ICS dose among patients with asthma7,8,10,11. Overall, we observed that a higher number of 
patients developed oral thrush when prescribed high daily dose of ICS compared with 
those prescribed low daily dose of ICS. However, this difference was only significant in 
the cohort comprising FP/SAL DPI and FP/SAL pMDI and, according to our exploratory 
analyses, it was likely driven by FP/SAL pMDI (for which the odds of developing oral 
thrush was 85% higher when the drug was prescribed at a high dose). The lack of dose 
effect in the BUD/FOR DPI arm was likely due to the fact that, as mentioned above, most 
patients (over 98%) were prescribed this therapy at low daily dose.  
In our study, we found that delivery of FP/SAL via a pMDI device was protective against 
oral thrush compared with delivery via a DPI device. This may reflect differential drug 
deposition in the respiratory tract between the two devices. Research has shown that FP 
delivered via a pMDI device produces a stronger bronchodilatory effect33 and achieves 
better disease control34 than FP delivered via a DPI device, likely because of greater ICS 
delivery to the lung35 and consequently less deposition in the throat. This may also explain 
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why we did not observe a significant effect of dose for FP/SAL DPI, as the amount of 
drug deposited in the throat may already saturate the tissue with ICS at low dose. With the 
pMDI device, instead, as our results indicate, the reduced oropharyngeal deposition of ICS 
would make the effect of different doses more quantifiable and clinically relevant. 
However, oropharyngeal deposition is influenced but many factors, including inhalation 
speed, inhaler technique, particle size, and pharyngeal and lower airway anatomy, among 
others36, which makes it challenging to truly assess differences in drug deposition between 
different drugs and inhalers. Thus, this hypothesis should be investigated further.  
Both drug deposition in the upper airways37,38 and oral candidiasis39 are reduced when 
using a pMDI with a spacer device, likely because the portion of the dose that usually 
impacts in the oropharynx is left in the spacer40. Accordingly, we found that fewer patients 
developed oral thrush when using FP/SAL pMDI with a spacer than without a spacer. This 
result was not statistically significant, however studying this association in a larger 
population could result in a statistically significant outcome. As poor inhaler and spacer 
technique is an issue in COPD41,42, it is possible that the occurrence of oral thrush could be 
further reduced by improving knowledge of proper use of spacers.  
In our study, approximately 40% of patients in each cohort were current smokers, in line 
with typical estimates of smoking prevalence in COPD43. Smoking is a known risk factor 
for developing oral thrush44. Thus, smoking may contribute to increased risk of oral thrush 
in patients with COPD who are smokers and are treated with ICS. However, because 
smoking status was a matching criterion in our study, it is unlikely that smoking habits 
introduced bias in our results. 
We found high rates of diabetes and eczema comorbidities among patients with COPD in 
this study (in the study cohorts and arms, diabetes was present in approximately 20% of 
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patients and eczema in approximately 15% of patients). We observed that incidence of 
oral thrush was significantly higher in patients with COPD and diabetes prescribed ICS 
compared with patients with COPD and diabetes prescribed non-ICS therapy (5.9% vs 
3.2%; p = 0.001). Because eczema can be caused by Candida albicans and diabetes is 
known to increase the risk of oral infections (owing to increased concentrations of glucose 
in saliva6,11), oral thrush may be a substantial issue for individuals with COPD and 
coexisting diabetes and/or eczema who are prescribed ICS. In these patients, a more 
careful consideration of which ICS should be prescribed, and at which dosage, may be 
appropriate. This aspect warrants further research.  
Study strengths and limitations 
This is one of a few studies exploring real-life incidence and determinants of oral thrush in 
COPD. A strength of this study is the cohort design; exposure to specific COPD therapies 
preceded the outcome measure, which allowed a stronger assessment of the causal 
association between ICS therapy, dose, and device type, and oral thrush. Our findings are 
also strengthened by the large sample sizes and by the use of data from primary care 
practices, particularly since the population investigated here is more representative of real-
life patients and of the clinical setting faced by practitioners than clinical trial populations 
23
. However, observational database studies may be limited by selection bias and residual 
confounding. Our goal in using a matching approach was to minimise cohort baseline 
differences and identify treatment cohorts of similar baseline COPD severity and other 
relevant determinants, as would occur with the randomisation process in a clinical trial. 
However, we cannot entirely exclude the possibility of systematic differences between 
patient cohorts due to some unobserved baseline characteristics. Another study limitation 
is the possibility of misdiagnosis or miscoding of oral thrush in routine primary care 
practice.  
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In the study cohorts, the incidence of oral thrush never exceeded 10%. In the literature, 
there is a high variability in the reported incidence of oral thrush with ICS use, with rates 
ranging from <1% to >70%, likely reflecting differences in diagnostic criteria, as reviewed 
elsewhere3,4. Although a true diagnosis of oral thrush would require confirmation by 
culture for Candida albicans, the infection is routinely diagnosed by visual examination of 
the oral lesions without further confirmation, with the exception of immunocompromised 
or hospitalised patients. Therefore, here and in other studies, misclassification of oral 
thrush cannot be excluded. It is also plausible that some patients would self-diagnose oral 
thrush, using previous experience, and visit community-based pharmacies to treat oral 
infections with over-the-counter medications without visiting their general practitioner. 
Thus, the incidence of oral thrush in this study may be underestimated and future research 
could be improved by collection of pharmacy data.  
Another explanation for the relatively low rate of oral thrush in our study may be poor 
adherence to therapy. Although adherence is difficult to assess using primary care 
prescribing data, poor adherence to inhaled treatment is a well-documented issue in 
chronic diseases, including asthma45 and COPD41. Cooper et al. (2015)12 found that 
patients who are more adherent to ICS experience more side-effects (including oral 
thrush). OPCRD, which was used in this study, collects data on prescriptions but it does 
not collect data on dispensing or actual use of drugs (or spacers); therefore, we cannot 
determine whether all patients effectively took their medications as prescribed. On the 
other hand, local side-effects of ICS may be the cause of poor compliance with 
therapy12,13. A clinical trial assessing long-term effects of ICS in COPD found that local 
side-effects, namely oral thrush and local irritation of the throat, were specified reasons for 
withdrawing from the trial20. This underlines the importance of investigating strategies to 
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reduce oral thrush with robust study designs, as good adherence is required to achieve 
appropriate disease control.  
CONCLUSIONS 
This study indicates that ICS treatment increases the incidence of oral thrush in patients 
with COPD and that this effect is dose-dependent for FP/SAL therapies. Of the therapies 
assessed in this study, and considering real-life prescribing patterns, FP/SAL pMDI and 
BUD/FOR DPI may represent more protective therapies against the local ICS side-effect 
oral thrush. In addition, our findings support implementation of guideline 
recommendations on spacer use, as additional reduction in oral thrush incidence may be 
achieved using spacer devices, especially for COPD patients with inhaler technique 
coordination problems. However, both device-related and patient-related factors can 
influence disease outcome when using inhaler medications. Therefore, the risk of side-
effects should be carefully balanced against therapeutic outcomes, patients’ preference, 
and patients’ inhaler technique when choosing the most appropriate inhaler therapy for 
individual patients. 
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Figure legends 
Fig. 1. Flow chart of participation in the study. This figure shows the number of patients in the 
FDC ICS/LABA (A) and non-ICS (B) cohorts at different stages of the study, including the number 
of potentially eligible individuals at the start of the study, the number of individuals lost after 
screening for inclusion/exclusion criteria, and the final eligible patients.   
Abbreviations: COPD = chronic obstructive pulmonary disease; FDC = fixed dose combination; 
ICS = inhaled corticosteroids; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic 
antagonist; LTRA = leukotriene receptor antagonist; QOF = quality and outcomes framework 
*FDC ICS/LABA therapy included initiation of budesonide/formoterol fumarate dihydrate (BUD/FOR) DPI, fluticasone 
propionate/salmeterol xinafoate (FP/SAL) (DPI or pMDI) or beclometasone dipropionate/formoterol fumarate dihydrate 
(BDP/FOR) (DPI or pMDI) at the index date 
†Non-ICS therapy included initiation of LABA, LAMA, or their combination at the index date 
Fig.2. Incidence of oral thrush by therapy and device. This figure shows the unadjusted and adjusted 
odds ratio (OR; 95% CI) for oral thrush for BUD/FOR DPI and FP/SAL pMDI arms (comparators) vs 
FP/SAL DPI arm (reference). In the comparison between FP/SAL pMDI and FP/SAL DPI, the intended 
inhaled corticosteroid (ICS) daily dose was not an a priori confounder and when added to the model the 
variable did not change the treatment effect, thus the fully adjusted OR is not shown for this cohort.  
Abbreviations: BUD/FOR = budesonide/formoterol fumarate dihydrate; DPI = dry powder 
inhaler; pMDI = pressurised metered-dose inhaler; FP/SAL = fluticasone propionate/salmeterol 
xinafoate 
*Adjusted for gastroesophageal reflux disease (GERD) in the baseline period  
†Adjusted for GERD in the baseline period and for intended ICS daily dose in the outcome period 
‡Adjusted for spacer device use in the outcome period 
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Tables 
Table 1: Baseline demographic and clinical characteristics of unmatched and matched 
cohorts (patients prescribed FDC ICS/LABA or non-ICS therapies) 
 Unmatched Matched* 
 
ICS/LABA† 
(n = 13,647) 
Non-ICS‡ 
(n = 10,043) 
ICS/LABA† 
(n = 8,255) 
Non-ICS‡ 
(n = 8,255) 
Age, mean (SD) 68.6 (10.1) 69.2 (9.9) 68.7 (9.9) 68.9 (9.7) 
Sex§, male, n (%) 7,597 (55.7) 5,754 (57.3) 4,699 (56.9) 4,699 (56.9) 
BMI§,¶ 
    
N (% non-missing) 13,211 (96.8) 9,778 (97.4) 8,076 (97.8) 8,076 (97.8) 
Mean (SD) 27.0 (5.9) 27.3 (5.7) 27.1 (5.8) 27.2 (5.7) 
Smoking Status§, n (%) 
    
N (% non-missing) 13,184 (96.6) 9,706 (96.6) 8,056 (97.6) 8,056 (97.6) 
Non-smoker 1,205 (9.1) 798 (8.2) 612 (7.6) 612 (7.6) 
Current smoker 5,160 (39.1) 3,925 (40.4) 3,288 (40.8) 3,288 (40.8) 
Ex-smoker 6,819 (51.7) 4,983 (51.3) 4,156 (51.6) 4,156 (51.6) 
FEV1 % predicted     
N (% non-missing) 12,541 (91.9) 9,400 (93.6) 7,574 (91.8) 7,739 (93.7) 
Mean (SD) 57.0 (19.4) 59.4 (18.8) 56.9 (19.2) 59.4 (18.8) 
mMRC score#, n (%) 
    
N (% non-missing) 12,199 (89.4) 9,146 (91.1) 7,326 (88.7) 7,524 (91.1) 
0 - 1 6,411 (52.6) 5,140 (56.2) 3,913 (53.4) 4,291 (57.0) 
≥ 2 5,788 (47.4) 4,006 (43.8) 3,413 (46.6) 3,233 (43.0) 
COPD exacerbations**, n (%) 
 
    
0 5,996 (43.9) 5,403 (53.8) 4,026 (48.8) 4,450 (53.9) 
1 3,905 (28.6) 2,683 (26.7) 2,597 (31.4) 2,173 (26.3) 
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2 2,067 (15.1) 1,192 (11.9) 941 (11.4) 1,014 (12.3) 
≥ 3 1,679 (12.3) 765 (7.6) 691 (8.4) 618 (7.5) 
Acute oral corticosteroid 
courses††, n (%)     
0 9,136 (66.9) 7,640 (76.1) 5,969 (72.3) 6,305 (76.4) 
1 2,887 (21.2) 1,688 (16.8) 1,650 (20.0) 1,371 (16.6) 
2 1,035 (7.6) 462 (4.6) 413 (5.0) 380 (4.6) 
≥ 3 589 (4.3) 253 (2.5) 223 (2.7) 199 (2.4) 
Antibiotic courses  
(lower resp. consult.‡‡), n (%)     
0 7,596 (55.7) 6,257 (62.3) 4,978 (60.3) 5,135 (62.2) 
1 3,196 (23.4) 2,245 (22.4) 1,950 (23.6) 1,843 (22.3) 
2 1,582 (11.6) 941 (9.4) 763 (9.2) 790 (9.6) 
≥ 3 1,273 (9.3) 600 (6.0) 564 (6.8) 487 (5.9) 
GOLD grade§§, n (%) 
    
N (% non-missing) 12,199 (89.4) 9,146 (91.1) 7,326 (88.7) 7,524 (91.1) 
A 3,054 (25.0) 3,073 (33.6) 2,069 (28.2) 2,562 (34.1) 
B 2,396 (19.6) 2,102 (23.0) 1,565 (21.4) 1,663 (22.1) 
C 3,357 (27.5) 2,067 (22.6) 1,844 (25.2) 1,729 (23.0) 
D 3,392 (27.8) 1,904 (20.8) 1,848 (25.2) 1,570 (20.9) 
COPD therapy§, n (%) 
    
None 3,232 (23.7) 2,532 (25.2) 2,628 (31.8) 2,139 (25.9) 
SABA and/or SAMA  6,138 (45.0) 6,342 (63.1) 4,816 (58.3) 5,305 (64.3) 
LABA (± SABA or ± SAMA) 1,459 (10.7) 674 (6.7) 422 (5.1) 422 (5.1) 
LAMA (± SABA or ± SAMA) 2,818 (20.6) 495 (4.9) 389 (4.7) 389 (4.7) 
Oral thrush§, n (%) 373 (2.7) 234 (2.3) 84 (1.0) 84 (1.0) 
Asthma¶¶, n (%) 1,342 (9.8) 719 (7.2) 800 (9.7) 591 (7.2) 
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Rhinitis¶¶, n (%) 1,043 (7.6) 807 (8.0) 592 (7.2) 630 (7.6) 
Pneumonia, n (%) 253 (1.9) 99 (1.0) 149 (1.8) 84 (1.0) 
GERD¶¶, n (%) 1,069 (7.8) 853 (8.5) 590 (7.1) 691 (8.4) 
Eczema, n (%) 1,979 (14.5) 1,561 (15.5) 1,175 (14.2) 1,255 (15.2) 
Diabetes§,¶¶, n (%) 2,729 (20.0) 2,043 (20.3) 1,516 (18.4) 1,516 (18.4) 
Charlson comorbidity index 
score## 
    
Mean (SD) 1.9 (3.9) 1.7 (3.8) 1.90 (3.9) 1.7 (3.8) 
Abbreviations: BMI = body mass index; FEV1 = forced expiratory volume in 1 second; GERD = 
gastroesophageal reflux disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = 
inhaled corticosteroids; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; mMRC 
score = modified Medical Research Council score; SABA = short-acting β2-agonist; SAMA = short-acting 
muscarinic antagonist 
*Cohorts matched on the following baseline variables: sex, age (±5 years), smoking status, BMI, COPD 
exacerbations (categorised), COPD therapy, nasal corticosteroids, oral thrush diagnosis and/or medication, and 
diabetes diagnosis and/or medication (see Table S1) 
†Fixed dose combination (FDC) ICS/LABA therapy, which included initiation of budesonide/formoterol 
fumarate dihydrate (BUD/FOR) DPI, fluticasone propionate/salmeterol xinafoate (FP/SAL) (DPI or pMDI) or 
beclometasone dipropionate/formoterol fumarate dihydrate (BDP/FOR) (DPI or pMDI) at the index date 
‡Non-ICS therapy included initiation of LABA, LAMA, or their combination at the index date; 10,043 are 
observations from 9,161 unique patients (patients may be included more than once with different first 
prescriptions for LABA, LAMA or their combination).  
§Matching variable 
¶Measured as kg/m2 
#mMRC score is used to assess the severity of breathlessness; both mMRC scores recorded in routine medical 
practice and patient mMRC scores were used, with the most recent score taking precedence 
**Moderate/severe exacerbations within the baseline period included occurrence of any of the following: (a) 
acute course of oral corticosteroids; (b) antibiotics prescribed with a lower respiratory consultation; (c) COPD-
related hospital admission to emergency department or hospital for COPD; (d) recorded hospitalisation 
admission on same day as a lower respiratory consultation (excluding the cases in which the only lower 
respiratory code recorded on that day was for a lung function test) 
††Defined as all courses that are not maintenance therapy and/or all courses for which dosing instructions 
suggest exacerbation treatment (e.g. tapering doses from 6 to 1, or 30 mg as directed) and/or all courses with 
no dosing instructions but unlikely to be maintenance therapy owing to prescription strength or frequency of 
prescriptions 
‡‡Lower respiratory consultation refers to lower respiratory diagnostic codes (including asthma, COPD, and 
lower respiratory tract infection [LRTI] read codes), or asthma/COPD review codes excluding any monitoring 
letter codes, or lung function and/or asthma monitoring AND any additional respiratory examinations, 
referrals, chest x-rays, or events. When >1 oral corticosteroid courses/antibiotic prescriptions occurred within 2 
weeks of each other, these events were considered to be the result of the same course 
§§GOLD grades based on 2011 GOLD guidelines14: A = Low risk, low symptom burden, mMRC = 0-1 and 
FEV1 ≥ 50% and/or low exacerbation rate (0-1/year); B = Low risk, higher symptom burden, mMRC ≥ 2 and 
FEV1 ≥ 50% and/or low exacerbation rate (0-1/year); C = High risk, low symptom burden, mMRC = 0-1 and 
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FEV1 < 50% and/or high exacerbation rate (≥ 2/year); D = High risk, higher symptom burden, mMRC ≥ 2 and 
FEV1 < 50% and/or high exacerbation rate (≥ 2/year) 
¶¶With a diagnostic code recorded at any time prior to or at the index date; asthma patients with asthma 
resolved codes were excluded 
##Calculated for the year prior to index date 
 
 
Table 2: Incidence of oral thrush in patients prescribed FDC ICS/LABA or non-ICS 
therapy in the matched cohorts  
 
n = 8,255 matched pairs* 
Baseline Outcome 
ICS/LABA† Non-ICS‡ ICS/LABA† Non-ICS‡ 
Oral thrush,  
n (%) 84 (1.0) 84 (1.0) 456 (5.5) 227 (2.7) 
Unadjusted OR (95% CI) - - 2.07 (1.76, 2.43) 1.00 
Adjusted OR (95% CI)§ - - 2.18 (1.84, 2.59) 1.00 
Abbreviations: ICS = inhaled corticosteroids; LABA = long-acting β2-agonist; OR = odds ratio 
*Cohorts matched on the following baseline variables: sex, age (±5 years), smoking status, body mass index (BMI), 
COPD exacerbations (categorised), COPD therapy, nasal corticosteroids, oral thrush diagnosis and/or medication, and 
diabetes diagnosis and/or medication (see Table S1)  
†Fixed dose combination (FDC) ICS/LABA therapy, which included initiation of budesonide/formoterol fumarate 
dihydrate (BUD/FOR) DPI, fluticasone propionate/salmeterol xinafoate (FP/SAL) (DPI or pMDI) or beclometasone 
dipropionate/formoterol fumarate dihydrate (BDP/FOR) (DPI or pMDI) at the index date 
‡Non-ICS therapy included initiation of LABA, long-acting muscarinic agonist (LAMA), or their combination at the 
index date 
§Adjusted for baseline confounders: categorised COPD-related consultations, categorised Charlson comorbidity index 
score, and categorised antibiotic courses  
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Table 3: Baseline demographic and clinical characteristics of patients in the matched 
BUD/FOR DPI + FP/SAL DPI and FP/SAL DPI + FP/SAL pMDI cohorts 
 Matched cohorts* 
 BUD/FOR 
DPI 
(n = 3,465) 
FP/SAL 
DPI 
(n = 3,465) 
FP/SAL 
pMDI 
(n = 3,800) 
FP/SAL 
DPI 
(n = 3,800) 
Age, mean (SD) 68.1 (9.7) 68.2 (9.6) 68.8 (10.0) 68.6 (9.8) 
Sex†, male, n (%) 1,994 (57.5) 1,994 (57.5) 2,157 (56.8) 2,157 (56.8) 
BMI‡ 
    
N (% non-missing) 3,368 (97.2) 3,344 (96.5) 3,686 (97.0) 3,667 (96.5) 
Mean (SD) 26.9 (5.9) 27.0 (6.0) 27.0 (5.8) 27.0 (5.9) 
Smoking Status†, n (%) 
    
N (% non-missing) 3,414 (98.5) 3,414 (98.5) 3,690 (97.1) 3,690 (97.1) 
Non-smoker 249 (7.3) 249 (7.3) 297 (8.0) 297 (8.0) 
Current smoker 1,323 (38.8) 1,323 (38.8) 1,470 (39.8) 1,470 (39.8) 
Ex-smoker 1,842 (54.0) 1,842 (54.0) 1,923 (52.1) 1,923 (52.1) 
FEV1 % predicted     
N (% non-missing) 3,216 (92.8) 3,181 (91.8) 3,501 (92.1) 3,481 (91.6) 
Mean (SD) 56.8 (19.1) 56.1 (19.4) 57.0 (19.1) 56.1 (19.3) 
mMRC score§ 
    
N (% non-missing) 3,172 (91.5) 3,114 (89.8) 3,361 (88.4) 3,401 (89.5) 
0 - 1 1,692 (53.3) 1,581 (50.8) 1,768 (52.6) 1,742 (51.2) 
≥ 2 1,480 (46.7) 1,533 (49.2) 1,593 (47.4) 1,659 (48.8) 
COPD exacerbations†¶, n (%) 
    
0 1,546 (44.6) 1,546 (44.6) 1,676 (44.1) 1,676 (44.1) 
1, 993 (28.7) 993 (28.7) 1,092 (28.7) 1,092 (28.7) 
2 522 (15.1) 522 (15.1) 571 (15) 571 (15) 
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≥ 3 404 (11.7) 404 (11.7) 461 (12.1) 461 (12.1) 
Acute oral corticosteroid courses#, 
n (%)     
0 2,299 (66.3) 2,346 (67.7) 2,592 (68.2) 2,567 (67.6) 
1 759 (21.9) 710 (20.5) 772 (20.3) 774 (20.4) 
2 265 (7.6) 260 (7.5) 280 (7.4) 291 (7.7) 
≥ 3 142 (4.1) 149 (4.3) 156 (4.1) 168 (4.4) 
Antibiotic courses  
(lower resp. consult.**), n (%)     
0 1,932 (55.8) 1,951 (56.3) 2,113 (55.6) 2,125 (55.9) 
1 828 (23.9) 808 (23.3) 889 (23.4) 882 (23.2) 
2 404 (11.7) 397 (11.5) 443 (11.7) 442 (11.6) 
≥ 3 301 (8.7) 309 (8.9) 355 (9.3) 351 (9.2) 
GOLD grade††, n (%) 
    
N (% non-missing) 3,172 (91.5) 3,114 (89.9) 3361 (88.4) 3401 (89.5) 
A 792 (25.0) 731 (23.5) 876 (26.1) 804 (23.6) 
B 633 (20.0) 624 (20.0) 658 (19.6) 675 (19.8) 
C 900 (28.4) 850 (27.3) 892 (26.5) 938 (27.6) 
D 847 (26.7) 909 (29.2) 935 (27.8) 984 (28.9) 
COPD therapy, n (%) 
    
None 841 (24.3) 846 (24.4) 876 (23.1) 926 (24.4) 
SABA and/or SAMA  1,622 (46.8) 1,441 (41.6) 1,741 (45.8) 1,584 (41.7) 
LABA (± SABA or ± SAMA) 317 (9.1) 332 (9.6) 488 (12.8) 359 (9.4) 
LAMA (± SABA or ± SAMA) 685 (19.8) 846 (24.4) 695 (18.3) 931 (24.5) 
Oral thrush†, n (%) 13 (0.4) 11 (0.3) 13 (0.3) 14 (0.4) 
Asthma§§, n (%) 320 (9.2) 313 (9) 391 (10.3) 344 (9.1) 
Rhinitis§§, n (%) 277 (8) 266 (7.7) 268 (7.1) 288 (7.6) 
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Pneumonia, n (%) 48 (1.4) 74 (2.1) 71 (1.9) 82 (2.2) 
GERD§§, n (%) 303 (8.7) 247 (7.1) 279 (7.3) 278 (7.3) 
Eczema, n (%) 493 (14.2) 519 (15) 511 (13.4) 581 (15.3) 
Diabetes†§§, n (%) 651 (18.8) 651 (18.8) 746 (19.6) 746 (19.6) 
Charlson comorbidity index score¶¶     
Mean (SD) 1.9 (3.8) 1.8 (3.9) 1.9 (4.0) 1.9 (4.0) 
Abbreviations: BMI = body mass index; BUD/FOR = budesonide/formoterol fumarate dihydrate; DPI = dry 
powder inhaler; FEV1 = forced expiratory volume in 1 second; FP/SAL =  fluticasone propionate/salmeterol 
xinafoate; GERD = gastroesophageal reflux disease; GOLD = Global Initiative for Chronic Obstructive Lung 
Disease; ICS = inhaled corticosteroids; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic 
antagonist; mMRC score = modified Medical Research Council score; pMDI = pressurised metered-dose 
inhaler; SABA = short-acting β2-agonist; SAMA = short-acting muscarinic antagonist  
*Cohorts matched on the following baseline variables: sex, age (±5 years), smoking status, COPD 
exacerbations (categorised), oral thrush diagnosis and/or medication, and diabetes diagnosis and/or medication 
(see Figure S2) 
†Matching variable   
‡Measured as kg/m2 
§mMRC score is used to assess the severity of breathlessness; both mMRC scores recorded in routine medical 
practice and patient mMRC scores were used, with the most recent score taking precedence 
¶Moderate/severe exacerbations within the baseline period included any of the following: (a) acute course of 
oral corticosteroids; (b) antibiotics prescribed with a lower respiratory consultation; (c) coded admission to 
emergency department or hospital for COPD; (d) recorded hospitalisation admission on same day as a lower 
respiratory consultation (excluding the cases in which the only lower respiratory code recorded on that day was 
for a lung function test) 
#Defined as all courses that are not maintenance therapy and/or all courses for which dosing instructions 
suggest exacerbation treatment (e.g. 6-1 reducing, or 30 mg as directed) and/or all courses with no dosing 
instructions but unlikely to be maintenance therapy owing to prescription strength or frequency of prescriptions 
**Lower respiratory consultation refers to lower respiratory diagnostic codes (including asthma, COPD, and 
lower respiratory tract infection [LRTI] read codes), or asthma/COPD review codes excluding any monitoring 
letter codes, or lung function and/or asthma monitoring AND any additional respiratory examinations, 
referrals, chest x-rays, or events. When >1 oral corticosteroid courses/antibiotic prescriptions occurred within 2 
weeks of each other, these events were considered to be the result of the same course 
††GOLD grades based on 2011 GOLD guidelines14: A = Low risk, low symptom burden, mMRC = 0-1 and 
FEV1 ≥ 50% and/or low exacerbation rate (0-1/year); B = Low risk, higher symptom burden, mMRC ≥ 2 and 
FEV1 ≥ 50% and/or low exacerbation rate (0-1/year); C = High risk, low symptom burden, mMRC = 0-1 and 
FEV1 < 50% and/or high exacerbation rate (≥ 2/year); D = High risk, higher symptom burden, mMRC ≥ 2 and 
FEV1 < 50% and/or high exacerbation rate (≥ 2/year) 
§§With a diagnostic code recorded at any time prior to or at the index date; asthma patients with asthma 
resolved codes were excluded 
¶¶Calculated for the year prior to index date 
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Table 4: Incidence of oral thrush by ICS dose  
BUD/FOR DPI + FP/SAL DPI 
cohort  Intended ICS daily dose
* (µg) Total 
 <500 500-999 ≥1000  
Oral thrush, n (%) 210 (5.6) 61 (6.8) 169 (7.4) 440 (6.3) 
Total, n (%) 3,747 (100) 899 (100) 2,284 (100) 6,930 (100) 
Unadjusted OR (95% CI) 1.00 1.22 (0.82, 1.83) 1.36 (1.06, 1.73)  
Adjusted OR (95% CI)† 1.00 1.33 (0.63, 2.82) 1.42 (0.70, 2.88)  
FP/SAL pMDI + FP/SAL DPI 
cohort Intended ICS daily dose
* (µg) Total 
 <500 500-999 ≥1000  
Oral thrush, n (%) 35 (4.7) 123 (5.4) 329 (7.2) 487 (6.4) 
Total, n (%) 748 (100) 2,300 (100) 4,552 (100) 7,600 (100) 
Unadjusted OR (95% CI) 1.00 1.36 (0.82, 2.24) 1.91 (1.20, 3.05)  
Adjusted OR (95% CI)‡ 1.00 1.47 (0.88, 2.46) 1.97 (1.22, 3.17)  
Abbreviations: BUD/FOR = budesonide/formoterol fumarate dihydrate; DPI = dry powder inhaler; FP/SAL = fluticasone 
propionate/salmeterol xinafoate; pMDI = pressurised metered-dose inhaler 
*Expressed in FP equivalent units 
†Adjusted for gastroesophageal reflux disease (GERD) in the baseline period and treatment group in the outcome period 
‡Adjusted for spacer device use and treatment group in the outcome period 
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≥ 2 prescriptions for FDC ICS/LABA in outcome
(n = 14,580)
COPD diagnosis
(n = 51,541)
Patient received a QOF COPD diagnosis 
code
No QOF COPD diagnosis code (n = 172,907)
Age ≥ 40 years
(n = 51,234)Patient aged ≥ 40 years at index date
Aged < 40 years at index date (n = 307)
Valid study period
(n = 35,672)
No ICS in baseline
(n = 17,483)
No prescriptions for ICS (alone or in 
combination) in baseline period
< 1 year of baseline or outcome practice data 
available (n = 15,562)
Prescriptions for ICS in baseline (n = 18,189)
All patients with a FDC ICS/LABA* prescription
(n = 224,448)
1 year of baseline and 1 year of outcome 
practice data available
Valid prescriptions in baseline
(n = 16,616)
No reliever/maintenance therapy 
prescriptions for COPD; or prescription for 
reliever only; or prescription for LAMA or 
LABA in baseline period
Prescriptions for LABA/LAMA (n = 718)
Prescriptions for LTRA (n = 108)
Prescriptions for other/unknown therapy (n = 41)
≥ 2 prescriptions for FDC ICS/LABA in 
outcome period
< 2 prescriptions for FDC ICS/LABA in outcome 
period (n = 2,036)
No maintenance oral corticosteroids in baseline
(n = 13,821)
No diagnosis for other chronic respiratory disease
(n = 13,647)
Final eligible patients in FDC ICS/LABA cohort
(n = 13,647)
Inclusion criteria
No prescriptions for maintenance oral 
corticosteroids in the baseline period
No diagnosis for a chronic respiratory 
disease other than COPD, asthma or 
bronchiectasis 
Exclusion criteria
Prescriptions for maintenance oral corticosteroids in 
the baseline period (n = 759)
Diagnosis for a chronic respiratory disease other 
than COPD, asthma or bronchiectasis (n = 174)
Figure 1
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≥ 2 prescriptions for LABA and/or LAMA in outcome
(n = 13,232)
COPD diagnosis
(n = 59,766)
Patient received a QOF COPD diagnosis 
code
No QOF COPD diagnosis code (n = 93,960)
Age ≥ 40 years
(n = 59,454)Patient aged ≥ 40 years at index date
Aged < 40 years at index date (n = 312)
Valid study period
(n = 43,042)
No ICS in baseline
(n = 15,725)
No prescriptions for ICS (alone or in 
combination) in baseline period
< 1 year of baseline or outcome practice data 
available (n = 16,412)
Prescriptions for ICS in baseline (n = 27,317)
All patients with a non-ICS† prescription
(n = 153,726)
1 year of baseline and 1 year of outcome 
practice data available
Valid prescriptions in baseline
(n = 15,599)
No reliever/maintenance therapy 
prescriptions for COPD; or prescription for 
reliever only; or prescription for LAMA or 
LABA in baseline period
Prescriptions for LABA/LAMA (n = 0)
Prescriptions for LTRA (n = 88)
Prescriptions for other/unknown therapy (n = 38)
≥ 2 prescriptions for LABA and/or LAMA in 
outcome period
< 2 prescriptions for LABA and/or LAMA in outcome 
period (n = 2,367)
No maintenance oral corticosteroids in baseline
(n = 12,663)
No diagnosis for other chronic respiratory disease
(n = 12,511)
Final eligible patients in non-ICS cohort
(n = 9,161 [10,043 unique first prescriptions])
No prescriptions for maintenance oral 
corticosteroids in the baseline period
No diagnosis for a chronic respiratory 
disease other than COPD, asthma or 
bronchiectasis 
Prescriptions for maintenance oral corticosteroids in 
the baseline period (n = 569)
Diagnosis for a chronic respiratory disease other 
than COPD, asthma or bronchiectasis (n = 152)
Inclusion criteria Exclusion criteria
No prescriptions for ICS in outcome period
(n = 9,161)
No prescriptions for ICS in the outcome 
period
≥ 1 prescription for ICS in the outcome period 
(n = 3,350)
Figure 1
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0.10 1.00 10.00
Reduced incidence for comparator Increased incidence for comparator
FP/SAL DPI = 1
Crude OR
Adjusted OR
Fully adjusted OR
0.78 (0.64, 0.95)
0.77 (0.63, 0.94)*
1.04 (0.54, 2.00)†
0.73 (0.60, 0.88)
0.67 (0.55, 0.82)‡
BUD/FOR DPI FP/SAL DPI 
Oral thrush Total Oral thrush Total
n (%) 196 (5.7) 3,465 (100) 244 (7.0) 3,465 (100)
FP/SAL pMDI FP/SAL DPI 
Oral thrush Total Oral thrush Total
n (%) 208 (5.5) 3,800 (100) 279 (7.3) 3,800 (100)
OR (95% CI)
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Highlights 
• Real-life occurrence of oral thrush in patients with COPD prescribed ICS is reported 
• Effect of different ICS types, doses, and delivery devices is investigated 
• Some therapeutic strategies are more protective than others against oral thrush  
 
 
 
